Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines global literature on post-finasteride syndrome, finding few studies link finasteride to rare sexual and systemic adverse effects; it is the first such review conducted in Spain.

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

In this study, researchers reviewed literature on topical delivery of finasteride for androgenetic alopecia, finding that liposomal gels with specific additives showed the highest skin permeation rates, suggesting potential for reducing systemic side effects compared to oral formulations.

This study found that finasteride-containing anionic liposomes enhanced skin retention and had moderate hair growth efficacy, suggesting potential for treating androgenetic alopecia with reduced systemic side effects.

The study reported that reducing finasteride particle size significantly improved its cellular permeation through prostate epithelial cells, though it had a lesser impact on systemic pharmacokinetics and tissue distribution in rats.

This study evaluated Finasteride-loaded nanostructured lipid carriers for topical use in treating androgenetic alopecia and found that these carriers offer sustained drug release and may reduce systemic side effects compared to oral administration.

This study found that in an androgenetic alopecia mouse model, phospholipid-bile salt mixed micelles for topical Finasteride delivery improved hair regrowth and reduced systemic absorption compared to a hydroalcoholic solution, suggesting a safer and more effective treatment option.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

In this study, finasteride-treated WAG/Rij rats showed a significant increase in spike-wave discharges when administered endogenous steroids THPROG and THDOC, indicating potential exacerbation of absence seizures.

This pharmacovigilance study found that certain systemic medications, including finasteride, bortezomib, and dupilumab, were disproportionately reported in association with eyelid disorders like blepharitis, meibomian gland dysfunction, and chalazia, suggesting these drugs may contribute to these conditions though benefits might still outweigh the risks.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This review discusses the pathophysiology, diagnosis, systemic associations, and treatments for female pattern hair loss and reports no new clinical findings.

This study reported that solid lipid nanoparticles of finasteride decorated with chitosan enhanced drug retention in skin layers, suggesting potential application in treating androgenic alopecia and benign prostate hyperplasia with fewer side effects.

This study reported that a 0.005% finasteride solution may encourage hair regrowth and reduce balding areas in patients with androgenic alopecia, without significant absorption or adverse effects.

This case report observed no hair regrowth after treating a woman with postmenopausal frontal fibrosing alopecia using systemic and local corticosteroids, suggesting the need for more innovative therapies.

Topical finasteride effectively treats hair loss with fewer side effects than the oral form.

Topical finasteride effectively treats hair loss with fewer side effects than the oral form.

This paper proposes a novel theory that certain symptoms of Post-Finasteride Syndrome may be caused by an overgrowth of hydrogen sulphide-producing bacteria in the small intestine, which acts as a mitochondrial toxin, with implications for treatment targeting the gut microbiome.

This theoretical paper proposes that a subset of Post-Finasteride Syndrome cases may be driven by a gut-derived toxic process involving hydrogen sulphide-producing bacteria, suggesting that the small intestinal microbiome could be a potential target for treating this condition.

This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.

This review discusses post-finasteride syndrome, highlighting occasional adverse sexual and systemic effects in men and women, but reports no new research findings while emphasizing the need for better education about the drug's risks.

This review discusses treatments for frontal fibrosing alopecia and lichen planopilaris, noting that systemic 5-alpha reductase inhibitors are most effective for stabilization and potential hair regrowth, but reports no new clinical results.

This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.

This study reported the successful development of finasteride-loaded poly(lactic-co-glycolic acid) nanoparticles, with varying encapsulation efficiencies, aiming to enhance drug delivery for hair growth while minimizing side effects, and noted that an in vivo study will follow to assess efficacy.

This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness.

This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.

This study suggests that glaucoma patients may face increased risk of optic nerve injury if prescribed medications that can lower blood pressure.

This study observed that DMSO-modified liposomes enhanced the topical delivery of finasteride, improving hair follicle density and growth phase ratio in a rat model of testosterone-induced alopecia.

This chapter reviews ethosomes for targeted drug delivery to the scalp in androgenetic alopecia and reports no clinical results; the authors emphasize reducing systemic side effects.

This study highlights the potential of polymeric micelles in enhancing the targeted delivery and efficacy of treatments for androgenetic alopecia, by offering improved retention on the scalp, extended release, and reduced systemic side effects compared to conventional therapies like minoxidil and finasteride.